“Rather than fear the cost impact” of the development of medications for rare diseases that “are among the first personalized medicines,” as a March 16 article and a March 23 editorial in the New York Times indicated, “we should embrace its potential to redirect resources toward treatments that work more effectively and safely because they are prescribed only to those patients most likely to benefit,”

More: continued here

This entry was posted on Wednesday, April 2nd, 2008 at 5:04 pm and is filed under Health Insurance / Medical Insurance. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.